Abstract
In the CME Review article by Sandhya Pruthi, Ruth Heisey and Therese Bevers, titled ‘Personalized assessment and management of women at risk for breast cancer in North America‘, which appeared in the March 2015 issue of Womens Health 11(2), 213–224 (2015), the below sentence appeared incorrectly as:
In Canada, currently only tamoxifen is approved by Health Canada for breast cancer risk reduction while in the USA both tamoxifen and ra-loxifine are approved by the US FDA for this specific indication.
The sentence should have appeared as:
Health Canada has not approved any medications for breast cancer risk reduction while in the USA both tamoxifen and raloxifine are approved by the US FDA for this specific indication.
The authors and editors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.